

A close-up photograph of two hands, one from the left and one from the right, holding each other's fingers to form a heart shape. The background is a bright, warm sunset or sunrise with a blurred landscape of trees and water. The overall tone is golden and hopeful.

Brighter

• Half-year report
January – June
2017.

Brighter AB (publ) 556736-8591

Half-year report January 1–June 30, 2017.

- Operating income amounted to SEK 21,475 thousand (SEK 12,687 thousand).
- Profit after financial items amounted to SEK -8,077 thousand (SEK -7,509 thousand).
- Earnings per share before dilution SEK -0.15 (-0.17 SEK).
- Earnings per share after dilution -0.15 SEK (-0.17 SEK)

Significant events during the period.

- 6/29/2017 – Brighter participates in Telia's Digital Healthcare event in Almedalen.
- 6/27/2017 – Increase in the number of shares in Brighter AB.
- 6/20/2017 – Brighter invited as speaker for diabetes event with Cambridge Wireless and Cambridge University Health Partners.
- 6/16/2017 – Analysguiden: "Countdown to launch".
- 6/16/2017 – Increase in the number of shares in Brighter AB.
- 5/26/2017 – Trading in warrants series TO3 2017/2020 commences on May 29, 2017.
- 5/19/2017 – Increase in the number of shares in Brighter AB.
- 5/16/2017 – Brighter selects AIS & Ericsson to launch the Actiste diabetes solution in Thailand.
- 5/15/2017 – Brighter fully subscribes to Camanio Care's new issue ahead of expansion in China.
- 5/8/2017 – New reconciliation day for the distribution of free options.
- 5/5/2017 – Increase in the number of shares in Brighter AB.
- 4/26/2017 – Brighter secures up to SEK 100 million funding for the launch of Actiste and issues free share warrants to existing shareholders.
- 4/25/2017 – Brighter launches actiste.com and demonstrates for the first time its unique Diabetes Service Actiste at Demo@Vitalis.
- 4/4/2017 – Brighter enters into a partnership with Indonesia Mampu to fight diabetes in Indonesia.
- 3/28/2017 – The Swedish Tax Agency raises the valuation of Brighter's Camanio Care shares by 60 percent.
- 3/17/2017 – Camanio Care is listed on the AktieTorget exchange.
- 2/20/2017 – Brighter signs an agreement with Sonat for a global logistics solution
- 1/5/2017 – Reconciliation date for the distribution of shares in Camanio Care AB to Brighter's shareholders.

Significant events after the period.

- 8/23/2017 – Increase in the number of shares in Brighter AB.



- 8/22/2017 – Brighter's main patent has been approved by United States Patent and Trademark Office.
- 8/15/2017 – Increase in the number of shares in Brighter AB.
- 8/14/2017 – Settlement with former development partner.
- 8/7/2017 – Brighter strengthens funding for autumn product launch.
- 8/3/2017 – Increase in the number of shares in Brighter AB.
- 7/24/2017 – Increase in the number of shares in Brighter AB.
- 7/13/2017 – Increase in the number of shares in Brighter AB.



A message from the CEO.

These are eventful times at Brighter, as we approach D Day and the launch of Actiste. We're still working towards our goal of launching before the start of next year, and it's great to see so many pieces of the puzzle, both large and small, falling into place.

There is no doubt that we're currently in an exciting phase, but the overriding feeling at the moment is that all the work we are doing is so concrete. We're now working on 0 series production, securing the subscription pre-orders from the county councils, building up the support organization, and finalizing the packaging design, logistics flows, marketing and communication. We're also organizing the CE labeling for both the physical device and the digital platform, including the interface and apps for users, relatives, healthcare staff, etc.

Of course, our focus from now on will be on preparing for the launch in Sweden, as well as in Indonesia and Thailand. In June we signed an agreement for the launch in Thailand with its largest operator AIS. The number of diabetics in Thailand is increasing rapidly; in 2015 approximately 4 million people were living with the disease. One of the major reasons why we've decided to launch in Thailand is because investments in healthcare are a priority in both the public and private sector. The fact that we have chosen Thailand and Indonesia as the first markets outside Sweden is primarily because of the market conditions there, giving us a great opportunity for us to establish ourselves and Actiste.

As well as these countries, we are also receiving enquiries from other countries and we are currently evaluating and assessing the quality of them. As we revealed in August, our main patent has been approved in the United States. We believe that there is huge potential in the United States because of the high number of diabetics, which is why we are planning on expanding there in the future.

We reached a milestone in the second quarter when we secured a major capital injection, and welcomed a major institutional investor as an owner in the form of L1 Capital at the same time. We have secured up to SEK 100 million of funding through the issuance of convertible notes and up to an additional SEK 115 million through associated warrants. The funding is divided into eight tranches over a period of three years, with SEK 30 million being provided in 2017.

In addition to the investment from L1 Capital, we also received an additional SEK 6.4 million from Recall Capital in July. In total, these investments mean that we now have secured the long-term capital we need to launch Actiste and to produce enough units to meet the initial demand.

It is satisfying to see that we have a growing interest for us as a company and for Actiste. This is shown not least by the fact that we are increasingly invited to speak at events, such as in Cambridge where we were presented how Actiste and The Benefit Loop revolutionize today's diabetes care, as well as Telia's event in Almedalen. As founder and CEO, I am confident that we will meet an exciting and successful autumn!



Truls Sjøstedt, Founder and CEO of Brighter AB.



A group of people are gathered around a table outdoors, enjoying a meal. In the foreground, a hand is reaching for a piece of food on a plate. The table is set with various dishes, including bread, potatoes, and shrimp. The background shows a sunset scene with trees and a warm glow.

Actiste

Limitless
control.

The people in the picture are models and are not associated with Actiste or diabetes.

Brighter in brief.

Brighter develops solutions for data-driven and mobile healthcare. Thanks to its intellectual capital and innovative aids the company is creating a more efficient care chain with the individual in focus. The aim is to simplify the information flow of relevant and reliable data between patient and care provider, to make it stronger and more efficient, and to enable the behavioral changes that are required.

Initially, Brighter is focusing on diabetes care, with the company's mobile-connected diabetes solution Actiste®. However, Brighter sees opportunities moving forward to act on a general level that spans several diseases and care directions. This will be done through The Benefit Loop®, Brighter's cloud-based service that continuously collects, processes and shares data on the user's terms. Brighter's IP platform can be applied and scaled in different clinical areas to create new and smart solutions for administration and follow-up of different drug therapies.

The company is listed on NASDAQ First North/BRIG.

For more information:

www.brighter.se

Vision.

We are Human Innovation.

Brighter's vision is to be the world leader in mobile health and data-driven care, serving as both the key to, and the market for, user-generated health data. The company develops innovative and smart technical solutions by adopting a user-friendly and intuitive design. Brighter's concept, products and services must help to change behaviors, to simplify treatment and to enhance the quality of life of its users, gather, analyze, process and market valid data as well as generate financial returns for the company and its investors.

Mission.

Drive behavioral change.

Brighter operates in the global market for data-driven healthcare, IoT ("Internet-of-Things") and mobile health. We use both state-of-the-art and groundbreaking innovations and adopt a clear position based on a strong and clear Swedish heritage.

The products and services provided by Brighter aim to drive quality improvements for everyone involved in the care chain. Brighter enables healthcare providers, patients and society to enhance the health of the individual. This is done by making it easier to change behaviors and by making more valid and effective measurement points/real life data available that can be shared continuously.

Strategy.

Brighter is a Swedish company listed on NASDAQ First North in Stockholm, Sweden. By establishing global collaboration models primarily with the companies and organizations in the industries concerned, we have laid the foundation for our success.



To this point, we have secured a global partnership with Ericsson for global connectivity and the management of our units, which has also been crucial for signing our first roll-out agreement with Telia Company for Sweden, Indosat Ooredoo for Indonesia, and AIS for Thailand. In order to ensure the highest quality along with global market access, we have opted for Sanmina as our partner for manufacturing and Sonat for logistics. We collaborate with companies that have in-depth knowledge and resources that Brighter can utilize and benefit from, and that see opportunities in working with Brighter as a way of pursuing their own innovation processes.

The dynamic that is created in combination with smart and cost-effective communications and marketing strategies is designed to ensure the rapid spread of the products and services that we offer on the market. And this will ultimately ensure financial growth both in the short and long term.

Brighter's offer.

Brighter develops products and services that meet a clear and easily identifiable user need in the care chain. At present, the Actiste diabetes solution is in its pre-launch phase and the Company estimates that it will be launched in the later part of the second half of 2017.

The Benefit Loop.

The Benefit Loop is a cloud-based service that processes, analyzes and returns health data in the treatment chain from various connected tools and apps. It has been developed to package and visualize relevant information and send feedback to the user in a smart and user-friendly way. Brighter's vision is to promote behavioral change. This includes not only developing smart assistive devices, but also becoming a leading company in mobile health and data-driven healthcare. We can help to provide a clearer picture of an individual's health by making reliable readings continually available. The individual can also personally decide who, for example a clinic, relative or researcher, can be given access to such health data. The Benefit Loop puts the patient and their disease at the center and offers a number of benefits based on different functions and perspectives.


Diabetes is our first clinical application, but there are many other chronic diseases that have a need for monitoring and treatment that can also be done remotely. In the long term, our thinking is to pave the way for other suppliers to connect different types of instruments and apps to The Benefit Loop.

By opening up the platform to others, we can obtain more data that can be used to improve treatments, utilize care resources more efficiently, plan care better, develop better drugs and treatment methods, but above all, improve the quality of life for people who live with a chronic disease.

The Benefit Loop comprises four helpful steps in one loop.

Treatment

The treatment of chronic diseases, of which diabetes is one example, must be simple to monitor in order to avoid secondary diseases and suffering for patients and high costs to society. Providing a better picture of



how the body responds makes it easier for the patient and healthcare to achieve the treatment goals.

Logging

By automatically logging as much information as possible you create a continuous flow of correct data, which can be used by the patient's doctor or nurse to optimize and improve treatment.

Analysis

The patient data readings that are automatically logged can be analyzed and used to adjust the treatment regimen or to justify a change in lifestyle. These readings can also be matched against the best methods of treatment and personal goals which can optimize the treatment results and increase the quality of life in the future. By significantly increasing access to information, healthcare receives better data for treating and supporting the patient, while doctors can identify patterns and predict consequences.

Improvement

Everyone involved in the care chain, i.e. the patient, care providers, society and other related parties such as the pharmaceutical industry, can benefit from being able to monitor patients and their diseases. By getting feedback, it will be possible to improve and check compliance with treatment, gain better supervision of medicines and their costs, and improve data and statistics on which the development of new drugs is based, which can increase the quality of the entire care chain.

Brighter's IP Platform.

Brighter's patent portfolio makes it possible for Brighter to log the measurement of a biomarker consistently, continuously and in a correlated manner as well as the actual injected dose of a drug in a single unit, and then transfer data continuously through a mobile connection. Actiste is the first application from our IP platform.

Actiste.

Diabetes is a globally growing public health crisis. In [Sweden, around 450,000 people live with diabetes](#); in the Nordic countries, the corresponding figure is 1.5 million people and globally, there are an estimated 415 million diabetics. The International Diabetes Federation ([IDF](#)) forecasts that there will be up to 642 million diabetics by 2040. With today's medicines and well-controlled diabetes, diabetics can enjoy a good quality of life as well as a long life. However, the risks associated with increased blood sugar levels must be taken seriously, and in this respect healthcare and patients have a major responsibility to work together to avoid damage to blood vessels caused by high blood sugar levels.

Over time, excessively high blood sugar creates problems in different organs in the body, such as in the form of heart, vascular, kidney and eye complications. There are also risks associated with the overdosage of insulin and immediate complications caused by excessively low blood sugar levels (hypoglycemia).

Actiste is a service that simplifies the lives of people with insulin-treated diabetes. Actiste groups the necessary functionality into a single flexible, mobile connected device. By using Actiste, the



user can measure blood glucose levels and inject insulin, and all the values are saved and can be shared automatically via the built-in mobile connection. Data can be shared with those selected by the user, such as family members and healthcare professionals. In this way, the care offered can help increase motivation in order to change behaviors and simplify follow-up.

With the mobile-connected Actiste, a completely new opportunity is introduced, which creates an overview of the disease, treatment and follow-up. Actiste, in addition to providing care, provides an overall picture and a high level of user-friendliness for the individual. At the same time, the burden of the healthcare sector's daily routines is reduced by automation of, for example, ordering consumables for patients.

To ensure a successful launch, we have established working relationships with a number of different partners. For the manufacturing process, we signed an agreement with Sanmina in 2016. Sanmina is a global Tier 1 supplier of integrated production solutions that has extensive experience of producing advanced medical devices, including millions of other diabetes tools. Sanmina also has a comprehensive launch and manufacturing capacity both in Sweden and around the world, holds ISO 13485 certification and has the capacity to scale up the process.

In February 2017, we opted for Sonat as a development partner for the company's logistics function for the forthcoming launch of Actiste®. Sonat specializes in developing, managing and running logistics processes, and will together with Brighter develop a robust logistics platform that facilitates growth and international expansion. Sonat will also act as an outsourced logistics function, which includes responsibility for forecasts, inventory control, availability, order planning, transportation administration, delivery monitoring and ongoing problem solving.

Having established a reliable manufacturing partner and logistics partner, an operator agreement with Telia Company for the Swedish market, as well as Indosat Ooredoo and AIS for Indonesia and Thailand respectively, the Actiste team has now been able to shift its focus from development and production to pre-launch.

As part of the pre-launch phase, we are initiating the marketing of Actiste directed at potential target groups. April saw Brighter represented in a number of major trade fairs for the industry. At Vitalis, which is the Nordic region's largest e-health fair, we exhibited and demonstrated Actiste on stage for the first time, and at the Diabetes forum, which is aimed at healthcare professionals, we took the opportunity to meet and connect with key stakeholders. In June we were also invited to speak about how Actiste and The Benefit Loop are revolutionizing diabetes care at the *"Unlocking 'remote monitoring' for effective diabetes care"* event in Cambridge. Just after the first six months of the year, we also took part in Telia's event in Almedalen.

In Indonesia, as part of our forthcoming launch, we have signed an agreement that will enable us to participate in and develop the first care initiative within the framework of Indonesia Mampu, a development program headed by Palladium and the Indonesian Government's National Team Secretariat for Accelerating Poverty Reduction (TNP2K). In this work, focus will be placed on the treatment and prevention of diabetes, an area where Brighter's expertise and technical know-how is a crucial component. The partnership will help Brighter to establish itself on the Indonesian market by strengthening the current work with Indosat Ooredoo and Ericsson.



In parallel with this development work, Brighter has commissioned focus groups that have given a very favorable response. An impressive 92% of participants in the focus groups say that Brighter has succeeded in making the process for diabetics much simpler and easier compared to existing equipment, which is significant confirmation that further reinforces our belief that Actiste will be beneficial when it is launched. The remaining 8% of the participants say that Brighter has made the process simpler and easier, which gives Actiste full marks – 100%.

Business Objectives.

The overall business objective for Brighter is to be at the forefront of mobile and data-driven health, by being the key to, and the market for, user-generated health data. In addition, we have developed a number of overall ambitions for our business and our products and solutions:

- Improved health.
- Reduced direct and indirect health costs.
- Drive behavioral change.
- Environmental benefits by adopting the concept of “cradle to cradle”.

Brighter has chosen to initially focus on diabetes as this disease is a growing global health problem where we see that by applying a range of solutions, we can enhance our care significantly and consequently improve the quality of life for the sick.

Market focus and target groups.

Brighter’s products and solutions are directed at a range of target groups that anyone can benefit from or who need our products or services. The primary target groups identified by Brighter are as follows:

- Consumers and patients.
- Mobile network operators.
- Payers: healthcare providers, governments/authorities, insurance companies, consumers, companies/employers.
- Clinical Research Organizations (CRO).
- R&D organizations and authorities, and the academic world.
- Pharmaceutical companies.

Business model.


Brighter's business model assumes that there are a number of different target groups (see above) for our products. These target groups have their specific driving forces or needs that underpin demand for our products and services. Brighter has also identified a number of ways on how to connect with our customers.

1. The agreement on roll-out and delivery specifications with mobile network operators (leverage impact on their customer base) in key markets for selling and reselling in the form of:
 - a. B2C, to end customers.
 - For Actiste – patients who live with diabetes and are treated with insulin at least once a day. They will pay as they already pay for a less convenient and less efficient



service than Brighter offers through Actiste and because Actiste will be sold as a subscription service at a competitive fixed fee.

- For the IP platform – to be notified later, but Brighter currently defines this market as consisting of patients living with a chronic disease that requires recurring measurement of biomarkers and injecting medication. But we also consider patients with long-term acute diseases that are tied to expensive treatments and require a disease or pharmaceutical biomarker measurement. The willingness to pay for applications (with its origin from the IP platform) is based on the fact that there is no other option, as new biological drugs (proteins or antibodies) are not absorbed by the body if taken orally.
 - b. B2B2C; to end customers via:
 - Public and private insurance that will pay because the service will generate significant savings.
 - Pharmaceutical companies that will pay because we offer them an opportunity to differentiate from competitors and access actual, continuous, effective and valid data.
2. Volume roll-out agreement with Clinical Research Organizations (CRO).
 - a. B2B, to CROs
 - For Actiste – This group will pay because Actiste provides them with a new way of selling its services that will be both cost-effective and generate more reliable data for its customers.
 3. Data volume agreement, B2B.
 - a. Pharmaceutical companies for clinical research that will pay because we facilitate reduced costs and continuous, effective and valid data.
 - b. CRO that will pay because we facilitate reduced costs and continuous, effective and valid data. Different from 2 above, as here we sell the data we have received permission from the users to sell.
 - c. Government authorities that will pay because we provide reduced costs and continuous, effective and valid data, including positioning data that can enable better community planning, regardless of the user's explicit consent.
 4. Marketplace for health data.
 - a. The IP platform, where Actiste is the first launch, is the key to collecting, processing and trading with actual, valid, continuous and effective data. This allows the owner of data – the user – and the buyer of the data – pharmaceutical companies, CROs, authorities, etc. – to trade data efficiently, with Brighter providing the transaction platform.
 5. Royalty payments based on existing and future patents currently consist of Brighter's patent portfolio of six patent families.



Possibility.

As the need for care in society increases, there will be a need to streamline healthcare by adopting a range of technical solutions. We see how new solutions in m-health and e-health are gaining momentum. With its strong patent portfolio and its unique instrument Actiste, Brighter has a real chance of succeeding in the huge diabetes market.

Size of the global market.

- Actiste Diabetes – Insulin.



150 million potential subscribers. About 37% of the total number of diabetes patients of 415 million should be using insulin on a daily basis (2016).

- Brighter's IP Platform.

There is major potential in applying the platform to administer many new drugs to improve the treatment of chronic diseases, particularly in oncology, cardiovascular endocrinology.

- Oncology: The IP platform can be applied to more than 66 new substances currently under clinical development. The potential exists in the drugs that can be developed from these and become relevant for the treatment of various cancers. Today, more than 15 million new cancer patients are registered every year.
- Cardiovascular endocrinology: There is also a great potential in this area with about 70 new drug candidates that can improve the lives of 600 million patients.

Please note that the above refers to the number of substances and drug candidates currently known by Brighter.

The size of the markets selected to date.

- Sweden: 150,000 subscribers (2016; 1.5% annual growth).
- Indonesia: 4 million subscribers (2016; 6% annual growth).
- Thailand: 1.5 million subscribers (2016; 6% annual growth).

Competitors in selected industries.

Direct:

- None today.

Indirect:

- BGM (Blood Glucose Meters): majority
- Continuous/Flash Glucose Meter (C/FGM): majority
- Insulin pens: majority
- Insulin pumps: majority
- Apps: majority
- Communication and motivation systems/platforms that address the compliance and effectiveness of the disease treatment.



Competitive advantages.

1. IP – Brighter currently has a family of six patents and a strategy for applying for at least two new patents per year. Brighter is in a unique position as the basic patent family refers to a solution patent in the intersection between medical technology and in vitro diagnostics. Subsequent patents serve as layers around the first, further expanding the strength and maturity of the patent portfolio. In addition, Brighter ensures registered trademarks for its products and services, such as Actiste®, Benefit Loop®, Digital Endorphins®, Brighter®, etc.
2. In terms of user experience, as described by our focus groups, 100% of respondents consider Actiste to be better or much better than their current solution. Please note that up until now, the focus groups do not consider all of Actiste Diabetes Management as a Service, but only the unit.
3. The business model – Brighter will be selling a subscription service and utilizing mobile operators as strategic and tactical partners, increasing the reach per invested marketing Swedish krona as well as providing synergy effects based on their regulatory and administrative infrastructures.
4. Price model – By focusing on data revenue potential from B2B customers and market transaction fees, Brighter can enjoy a highly competitive position in both the B2C and B2B2C segments.



The team.

The team can boast over 200 years of combined experience from various backgrounds, including but not limited to:

Medical Devices | Pharmacology | Diabetology | Endocrinology | Oncology | Behavioral Science | Business Development | Project Financing | Software Development | Development of Mobile Applications | Market Launches | Advertising | Quality Assurance & Regulatory Affairs | Medical Affairs | Mechanical Development | Electronics Development | Marketing & Sales | Back-end Development | etc.

Impact.

Brighter sees a major potential for the following changes.

- 1) The treatment of chronic diseases using injectable drugs, enhances compliance with treatment through improved user experience and a subscription model, allowing space to move toward agreed treatment targets.
- 2) The perception of patients in terms of their condition and the costs for this, by giving them the opportunity to share and market their tasks 1) in favor of research and 2) to take control of their own costs for the treatment.
- 3) The clinical research and public research industry by offering a marketplace where they can access real life, valid, continuous and effective user-generated health data, at a market value.



The share.

Brighter AB (publ) is listed on NASDAQ First North with the stock symbol BRIG. NASDAQ First North is a Multilateral Trading Facility (MTF). As of June 30, 2017, 53,506,020 shares were issued. All shares have equal rights to company profits and assets.

The Brighter Certified Adviser on NASDAQ OMX First North is Remium Nordic AB.

Insider holdings.

Shares.	2016-06-30	Change.	2017-06-30
Truls Sjöstedt – CEO	5,666,140	+ 33,350	5,699,490
Henrik Norström - COO	588,951	+ 36,800	625,751
Gert Westergren – Chariman	664,296	- 128,162	536,134
Lars Flening – Board member	212,839	0	212,839
Afsaneh Ghatan Bauer – Board member	51,600	0	51,600
Sara Murby Forste – Board member	23,100	0	23,100
Jan Stålemark – Board member	18,670	0	18,670
Petra Kaur Ljungman – Board member	14,725	0	14,725
Nadezda Ershova – Head QA/RA	5,889	0	5,889

Warrants.	2016-06-30	Change.	2017-06-30
Henrik Norström - COO	988,085	+ 800,000	1,788,085
Truls Sjöstedt – CEO	1,277,755	0	1,277,755
Gert Westergren – Chairman	286,495	0	286,495
Åsa Hallin Dahlberg – Head of Development & Production	200,000	0	200,000
Sara Murby Forste – Board member	182,500	0	182,500
Afsaneh Ghatan Bauer – Board member	131,650	0	131,650
Jan Stålemark – Board member	125,000	0	125,000
Nadezda Ershova – Head QA/RA	19,277	0	19,277
Petra Kaur Ljungman – Board member	16,500	0	16,500



Income statement in SEK thousand (summary).

	2017-01-01 2017-06-30	2016-01-01 2016-06-30
Operating income.	21,475	12,687
Sales.	646	0
Capitalized production costs.	20,314	12,537
Other income.	515	150
Direct costs.	0	0
Other external costs.	-24,360	-16,312
Staff costs.	-4,297	-3,667
Depreciation, amortization and impairment.	-99	-93
Other costs.	-9	-94
Operating profit.	-7,290	-7,479
Profit from other items.	-786	-29
Profit after financial items.	-8,077	-7,509
Profit for the period.	-8,077	-7,509
Earnings per share, before dilution.	-0,15	-0,17
Earnings per share, after dilution.	-0,15	-0,17
Number of shares, before dilution.	53,506,020	45,937,263
Number of shares, after dilution.	65,650,719	51,437,263
Average number of shares, before dilution.	52,915,422	43,775,542
Average number of shares, after dilution.	65,060,121	49,275,542



Balance sheet in SEK thousand (summary).

	2017-06-30	2016-06-30
ASSETS.		
Capitalized expenditure.	63,987	34,405
Patents and trademarks.	3,014	2,388
Property, plant and equipment.	240	403
Financial assets.	12,622	14,613
Total fixed assets.	79,863	51,809
Short-term receivables.	6,968	2,474
Cash at bank and in hand.	2,756	6,269
Total current assets.	9,723	8,742
TOTAL ASSETS.	89,587	60,552
EQUITY AND LIABILITIES.		
Share capital.	2,675	2,069
Share premium.	120,382	78,667
Development expenses fund.	42,266	0
Issue proceeds.	0	10,435
Profit carried forward.	-99,994	-40,241
Projected profit.	-8,077	-7,509
Total Equity.	57,252	43,422
Convertible loan.	16,787	
Long-term liabilities.	6	6
Total long-term liabilities.	16,792	6
Trade payables.	7,242	3,830
Other liabilities.	6,460	11,909
Accruals and deferred income.	1,847	1,385
Total current liabilities.	15,548	17,124
TOTAL EQUITY AND LIABILITIES.	89,587	60,552
PLEDGED ASSETS.	2,208	2,208



Actiste



The diabetes care
of the future is
already here.

Cash flow statement in SEK thousand (summary).

	2017-01-01 2017-06-30	2016-01-01 2016-06-30
Cash flow from operating activities before changes in working capital.	-7,977	-7,422
Changes in working capital.		
Decrease/increase in current receivables.	-2,530	-1,173
Decrease/increase in current liabilities.	785	-2,911
CASH FLOW FROM OPERATING ACTIVITIES.	-9,722	-11,506
Investment activities.		
Acquisition of intangible fixed assets.	-20,459	-12,724
Acquisition of tangible fixed assets.	0	0
Acquisition of financial assets.	3,550	0
Changes in stock.	0	0
CASH FLOW FROM INVESTMENT ACTIVITIES.	-16,909	-12,724
Financing activities.		
Loans raised/Amortized loans.	16,781	8,500
New share issue (net after issue costs).	10,877	21,279
Client funds.	0	0
CASH FLOW FROM FINANCING ACTIVITIES.	27,657	29,779
Cash flow for the period.	1,026	5,549
Opening cash and cash equivalents.	1,730	720
CLOSING CASH AND CASH EQUIVALENTS.	2,756	6,269



Accounting principles.

This half-year report has been prepared in accordance with the Swedish Annual Accounts Act and the general advice of the Swedish Accounting Standards Board BFNAR 2012:1 Annual Report and Consolidated Financial Statements unless otherwise stated. Brighter AB (publ) is the parent company of a group, but does not prepare consolidated financial statements with reference to the exception rule in the Swedish Annual Accounts Act Chapter 7 Section 3 (smaller group).

Dates for financial information.

Interim report Jan-Sep 2017: 2017-11-24.

Year-end report 2017: 2018-02-23

Interim report Jan-Mar 2018: 2018-04-20

Half-year report Jan-Jun 2018: 2018-08-24

Company audit.

This half-year report has not been audited by the company's auditors.

Certified Adviser.

The Brighter Certified Adviser on the Nasdaq OMX First North is Remium Nordic AB.

Submission of the half-year report.

Stockholm August 25, 2017.

Brighter AB (publ).

The Board.

For more information, please contact:

Truls Sjöstedt, CEO

Telephone: +46 709 73 46 00

E-mail: truls.sjostedt@brighter.se

Henrik Norström, COO

Telephone: +46 733 40 30 45

E-mail: henrik.norstrom@brighter.se



Brighter AB (publ)

Corp. ID. 556736-8591

Norgegatan 2 4tr | SE-164 28 Kista | Sweden

tel: +46 8 55 00 88 20 | fax: +46 8 55 00 88 30

